AU2015298876B2 - Indoles for use in influenza virus infection - Google Patents
Indoles for use in influenza virus infection Download PDFInfo
- Publication number
- AU2015298876B2 AU2015298876B2 AU2015298876A AU2015298876A AU2015298876B2 AU 2015298876 B2 AU2015298876 B2 AU 2015298876B2 AU 2015298876 A AU2015298876 A AU 2015298876A AU 2015298876 A AU2015298876 A AU 2015298876A AU 2015298876 B2 AU2015298876 B2 AU 2015298876B2
- Authority
- AU
- Australia
- Prior art keywords
- mmol
- amino
- nmr
- mhz
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 CC(C=*)=C(C)N* Chemical compound CC(C=*)=C(C)N* 0.000 description 8
- ULPOWWJRVSWRIN-UHFFFAOYSA-N CC(C)(C(CC(O)=O)Nc1nc(-c2c[nH]c(c(F)c3)c2cc3F)ncc1F)C(N(C)C)=O Chemical compound CC(C)(C(CC(O)=O)Nc1nc(-c2c[nH]c(c(F)c3)c2cc3F)ncc1F)C(N(C)C)=O ULPOWWJRVSWRIN-UHFFFAOYSA-N 0.000 description 1
- OBSACSBMTRJNPH-DTWKUNHWSA-N CC(C)(C)OC(N[C@H](CCC1)C[C@H]1N)=O Chemical compound CC(C)(C)OC(N[C@H](CCC1)C[C@H]1N)=O OBSACSBMTRJNPH-DTWKUNHWSA-N 0.000 description 1
- QWSRWKWHNGDZEH-VHSXEESVSA-N CC(C)(C)OC(N[C@H](CCC1)C[C@H]1Nc1nc(Cl)ncc1F)=O Chemical compound CC(C)(C)OC(N[C@H](CCC1)C[C@H]1Nc1nc(Cl)ncc1F)=O QWSRWKWHNGDZEH-VHSXEESVSA-N 0.000 description 1
- KCXHZFYNZSHRFB-UHFFFAOYSA-N CC(C)(C)OC([n]1c(c(F)cc(Cl)c2)c2c(B2OC(C)(C)C(C)(C)O2)c1)=O Chemical compound CC(C)(C)OC([n]1c(c(F)cc(Cl)c2)c2c(B2OC(C)(C)C(C)(C)O2)c1)=O KCXHZFYNZSHRFB-UHFFFAOYSA-N 0.000 description 1
- VNBYLAQTENYYTJ-UHFFFAOYSA-N CC(C)(C)OC([n]1c(c(F)cc(Cl)c2)c2c(I)c1)=O Chemical compound CC(C)(C)OC([n]1c(c(F)cc(Cl)c2)c2c(I)c1)=O VNBYLAQTENYYTJ-UHFFFAOYSA-N 0.000 description 1
- XNYRTAKQLFILLM-UHFFFAOYSA-N CC(C)(CC(C1)NC(c2c[nH]cn2)=O)CC1Nc1nc(Cl)ncc1F Chemical compound CC(C)(CC(C1)NC(c2c[nH]cn2)=O)CC1Nc1nc(Cl)ncc1F XNYRTAKQLFILLM-UHFFFAOYSA-N 0.000 description 1
- ALHMBXWAZOZVSM-QWHCGFSZSA-N CC(N[C@@H](CCC1)C[C@@H]1Nc1nc(C)c(C)cc1F)=O Chemical compound CC(N[C@@H](CCC1)C[C@@H]1Nc1nc(C)c(C)cc1F)=O ALHMBXWAZOZVSM-QWHCGFSZSA-N 0.000 description 1
- DTPOISCAXTWFJM-WDEREUQCSA-N CC(N[C@@H](CCC1)C[C@@H]1Nc1nc(C)ncc1F)=O Chemical compound CC(N[C@@H](CCC1)C[C@@H]1Nc1nc(C)ncc1F)=O DTPOISCAXTWFJM-WDEREUQCSA-N 0.000 description 1
- UCFSYHMCKWNKAH-UHFFFAOYSA-N CC1(C)OBOC1(C)C Chemical compound CC1(C)OBOC1(C)C UCFSYHMCKWNKAH-UHFFFAOYSA-N 0.000 description 1
- GDQLRKVIULWAEQ-JRASRSEESA-N COC([C@@H](C1CCC2CC1)C2Nc1nc(Cl)ncc1F)=O Chemical compound COC([C@@H](C1CCC2CC1)C2Nc1nc(Cl)ncc1F)=O GDQLRKVIULWAEQ-JRASRSEESA-N 0.000 description 1
- LLCQYRINGDWUNV-HIFRSBDPSA-N C[C@H](CCC1)C[C@H]1Nc1nc(-c2c[n](C(OC(C)(C)C)=O)c(c(F)c3)c2cc3Cl)ncc1F Chemical compound C[C@H](CCC1)C[C@H]1Nc1nc(-c2c[n](C(OC(C)(C)C)=O)c(c(F)c3)c2cc3Cl)ncc1F LLCQYRINGDWUNV-HIFRSBDPSA-N 0.000 description 1
- DQXNTSXKIUZJJS-UHFFFAOYSA-N Cc(c(Cl)n1)cnc1Cl Chemical compound Cc(c(Cl)n1)cnc1Cl DQXNTSXKIUZJJS-UHFFFAOYSA-N 0.000 description 1
- VTWFNANUARVGQZ-CELQXHKJSA-N Cc(nc1N[C@H](CCC2)C/C2=N/C(c2ccccn2)=O)ncc1F Chemical compound Cc(nc1N[C@H](CCC2)C/C2=N/C(c2ccccn2)=O)ncc1F VTWFNANUARVGQZ-CELQXHKJSA-N 0.000 description 1
- ZCMZOMSABWKMNM-KIYNQFGBSA-N Cc1c(C(N[C@@H](CCC2)CC2Nc(nc(c(C#N)c2)Cl)c2F)=O)nc[o]1 Chemical compound Cc1c(C(N[C@@H](CCC2)CC2Nc(nc(c(C#N)c2)Cl)c2F)=O)nc[o]1 ZCMZOMSABWKMNM-KIYNQFGBSA-N 0.000 description 1
- IGBOXGVHHSLXPE-UHFFFAOYSA-N N#CCc1n[nH]cc1 Chemical compound N#CCc1n[nH]cc1 IGBOXGVHHSLXPE-UHFFFAOYSA-N 0.000 description 1
- NFWZARAFTINKJK-QWHCGFSZSA-N N[C@@H](CCC1)C[C@@H]1NC(OCc1ccccc1)=O Chemical compound N[C@@H](CCC1)C[C@@H]1NC(OCc1ccccc1)=O NFWZARAFTINKJK-QWHCGFSZSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14180331 | 2014-08-08 | ||
| EPEP14180331.2 | 2014-08-08 | ||
| PCT/EP2015/068257 WO2016020526A1 (en) | 2014-08-08 | 2015-08-07 | Indoles for use in influenza virus infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2015298876A1 AU2015298876A1 (en) | 2017-02-02 |
| AU2015298876B2 true AU2015298876B2 (en) | 2020-02-13 |
Family
ID=51298610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2015298876A Ceased AU2015298876B2 (en) | 2014-08-08 | 2015-08-07 | Indoles for use in influenza virus infection |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10597390B2 (enExample) |
| EP (1) | EP3177609A1 (enExample) |
| JP (1) | JP6577570B2 (enExample) |
| KR (1) | KR102488479B1 (enExample) |
| CN (1) | CN106573920B (enExample) |
| AU (1) | AU2015298876B2 (enExample) |
| BR (1) | BR112017002370B1 (enExample) |
| CA (1) | CA2954751C (enExample) |
| CL (1) | CL2017000309A1 (enExample) |
| EA (1) | EA201790266A1 (enExample) |
| IL (1) | IL250408B (enExample) |
| MA (1) | MA40547A (enExample) |
| MX (1) | MX381488B (enExample) |
| PH (1) | PH12017500207A1 (enExample) |
| SG (1) | SG11201700956VA (enExample) |
| UA (1) | UA124609C2 (enExample) |
| WO (1) | WO2016020526A1 (enExample) |
| ZA (1) | ZA201700952B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2442809T3 (en) | 2009-06-17 | 2016-12-19 | Vertex Pharma | Inhibitors of the replication of influenza virus |
| UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
| SG11201700956VA (en) | 2014-08-08 | 2017-03-30 | Janssen Sciences Ireland Uc | Indoles for use in influenza virus infection |
| MA42422A (fr) | 2015-05-13 | 2018-05-23 | Vertex Pharma | Inhibiteurs de la réplication des virus de la grippe |
| JP6704416B2 (ja) | 2015-05-13 | 2020-06-03 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | インフルエンザウイルスの複製の阻害剤を調製する方法 |
| WO2017097234A1 (en) | 2015-12-09 | 2017-06-15 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication, application methods and uses thereof |
| EP3400225B1 (en) * | 2016-01-07 | 2021-11-10 | Janssen Sciences Ireland Unlimited Company | Pentanoic acids substituted by pyrrolo-[2-3,b]pyrimidine-pyridines for the treatment of influenza viral infections |
| WO2017133670A1 (en) * | 2016-02-05 | 2017-08-10 | Savira Pharmaceuticals Gmbh | Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza |
| WO2018033082A1 (en) * | 2016-08-16 | 2018-02-22 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication, application methods and uses thereof |
| CN109641868B (zh) * | 2016-08-30 | 2021-12-03 | 广东东阳光药业有限公司 | 流感病毒复制抑制剂及其使用方法和用途 |
| RU2727772C1 (ru) * | 2016-09-05 | 2020-07-23 | Гуандун Рэйновент Байотек Ко., Лтд. | Производные пиримидина против вируса гриппа |
| WO2018108125A1 (en) | 2016-12-15 | 2018-06-21 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication and uses thereof |
| CA3047404A1 (en) | 2016-12-23 | 2018-06-28 | Aquinnah Pharmaceuticals, Inc. | Compounds, compositions and methods of use |
| CN108276401B (zh) | 2017-01-05 | 2020-12-22 | 广东东阳光药业有限公司 | 流感病毒复制抑制剂及其用途 |
| CN110446711B (zh) | 2017-03-02 | 2022-02-15 | 广东东阳光药业有限公司 | 流感病毒复制抑制剂及其用途 |
| CN108727369B (zh) * | 2017-04-25 | 2023-06-09 | 广东东阳光药业有限公司 | 流感病毒复制抑制剂及其用途 |
| NZ767352A (en) * | 2018-03-05 | 2023-05-26 | Guangdong Raynovent Biotech Co Ltd | Crystal form and salt form of pyridopyrazole compound and preparation method therefor |
| US12252487B2 (en) | 2019-07-22 | 2025-03-18 | Guangdong Raynovent Biotech Co., Ltd. | Dominant salt forms of pyrimidine derivatives, and crystal forms thereof |
| CN113045475A (zh) * | 2019-12-27 | 2021-06-29 | 上海泓博智源医药股份有限公司 | 一种5-溴-7-甲基吲哚的制备方法 |
| KR20230079003A (ko) * | 2020-07-20 | 2023-06-05 | 니도 바이오사이언시스, 인코포레이티드 | 안드로겐 수용체 조절제로서의 인돌 화합물 |
| WO2022057842A1 (en) * | 2020-09-18 | 2022-03-24 | Sunshine Lake Pharma Co., Ltd. | Preparation method of substituted pyrimidine piperazine compounds |
| IL320191A (en) * | 2022-10-12 | 2025-06-01 | Maze Therapeutics Inc | Solute carrier family 6A member 19 inhibitors (SLC6A19) and methods of using them |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012083122A1 (en) * | 2010-12-16 | 2012-06-21 | Vertex Pharmaceutical Incorporated | Inhibitors of influenza viruses replication |
| WO2013019828A1 (en) * | 2011-08-01 | 2013-02-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7507826B2 (en) | 2004-03-30 | 2009-03-24 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of JAK and other protein kinases |
| TW201412738A (zh) | 2006-01-17 | 2014-04-01 | Vertex Pharma | 適合作為傑納斯激酶（ｊａｎｕｓ ｋｉｎａｓｅ）抑制劑之氮雜吲哚 |
| DK2442809T3 (en) * | 2009-06-17 | 2016-12-19 | Vertex Pharma | Inhibitors of the replication of influenza virus |
| JP5876051B2 (ja) * | 2010-09-08 | 2016-03-02 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | インフルエンザウィルス感染の治療に使用するためのインダゾール誘導体 |
| AU2011343642A1 (en) * | 2010-12-16 | 2013-05-02 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| WO2013030138A1 (en) | 2011-09-01 | 2013-03-07 | F. Hoffmann-La Roche Ag | Pyrrolopyrazine kinase inhibitors |
| WO2013184985A1 (en) | 2012-06-08 | 2013-12-12 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| EP3068776B1 (en) | 2013-11-13 | 2019-05-29 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| SG11201700956VA (en) | 2014-08-08 | 2017-03-30 | Janssen Sciences Ireland Uc | Indoles for use in influenza virus infection |
| AR101401A1 (es) | 2014-08-08 | 2016-12-14 | Bayer Cropscience Ag | Derivados de bipirazol, sustituidos con halógeno |
| AR101448A1 (es) | 2014-08-08 | 2016-12-21 | Bayer Cropscience Ag | Compuestos sustituidos por halógeno |
| CN104592038A (zh) | 2015-01-12 | 2015-05-06 | 烟台万润精细化工股份有限公司 | 一种5,5-二甲基-1,3-环己二胺的制备方法 |
-
2015
- 2015-08-07 SG SG11201700956VA patent/SG11201700956VA/en unknown
- 2015-08-07 CN CN201580042406.9A patent/CN106573920B/zh not_active Expired - Fee Related
- 2015-08-07 EP EP15750365.7A patent/EP3177609A1/en not_active Withdrawn
- 2015-08-07 WO PCT/EP2015/068257 patent/WO2016020526A1/en not_active Ceased
- 2015-08-07 MX MX2017001752A patent/MX381488B/es unknown
- 2015-08-07 US US15/501,730 patent/US10597390B2/en not_active Expired - Fee Related
- 2015-08-07 AU AU2015298876A patent/AU2015298876B2/en not_active Ceased
- 2015-08-07 JP JP2017506964A patent/JP6577570B2/ja not_active Expired - Fee Related
- 2015-08-07 CA CA2954751A patent/CA2954751C/en active Active
- 2015-08-07 EA EA201790266A patent/EA201790266A1/ru unknown
- 2015-08-07 UA UAA201702154A patent/UA124609C2/uk unknown
- 2015-08-07 MA MA040547A patent/MA40547A/fr unknown
- 2015-08-07 KR KR1020177005979A patent/KR102488479B1/ko active Active
- 2015-08-07 BR BR112017002370-9A patent/BR112017002370B1/pt not_active IP Right Cessation
-
2017
- 2017-02-02 PH PH12017500207A patent/PH12017500207A1/en unknown
- 2017-02-02 IL IL250408A patent/IL250408B/en active IP Right Grant
- 2017-02-07 CL CL2017000309A patent/CL2017000309A1/es unknown
- 2017-02-07 ZA ZA2017/00952A patent/ZA201700952B/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012083122A1 (en) * | 2010-12-16 | 2012-06-21 | Vertex Pharmaceutical Incorporated | Inhibitors of influenza viruses replication |
| WO2013019828A1 (en) * | 2011-08-01 | 2013-02-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
Also Published As
| Publication number | Publication date |
|---|---|
| JP6577570B2 (ja) | 2019-09-18 |
| CA2954751C (en) | 2023-01-17 |
| KR102488479B1 (ko) | 2023-01-12 |
| ZA201700952B (en) | 2018-12-19 |
| IL250408A0 (en) | 2017-03-30 |
| BR112017002370B1 (pt) | 2022-11-22 |
| MA40547A (fr) | 2017-06-14 |
| CA2954751A1 (en) | 2016-02-11 |
| KR20170039275A (ko) | 2017-04-10 |
| MX2017001752A (es) | 2018-02-08 |
| IL250408B (en) | 2020-08-31 |
| CN106573920A (zh) | 2017-04-19 |
| CL2017000309A1 (es) | 2017-08-18 |
| PH12017500207B1 (en) | 2017-07-10 |
| US20170226102A1 (en) | 2017-08-10 |
| UA124609C2 (uk) | 2021-10-20 |
| JP2017523225A (ja) | 2017-08-17 |
| PH12017500207A1 (en) | 2017-07-10 |
| EP3177609A1 (en) | 2017-06-14 |
| MX381488B (es) | 2025-03-12 |
| SG11201700956VA (en) | 2017-03-30 |
| US10597390B2 (en) | 2020-03-24 |
| AU2015298876A1 (en) | 2017-02-02 |
| BR112017002370A2 (pt) | 2017-12-05 |
| EA201790266A1 (ru) | 2017-06-30 |
| WO2016020526A1 (en) | 2016-02-11 |
| CN106573920B (zh) | 2020-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6577570B2 (ja) | インフルエンザウイルス感染に使用するためのインドール類 | |
| KR102531340B1 (ko) | 인플루엔자 바이러스 감염에 사용하기 위한 피롤로피리미딘 | |
| AU2017209925B2 (en) | Aryl substituted pyrimidines for use in influenza virus infection | |
| ES2882671T3 (es) | Indoles heterocíclicos para su uso en infecciones por el virus de la gripe | |
| AU2012290127A1 (en) | Inhibitors of influenza viruses replication | |
| AU2017205261B2 (en) | Functionalized pentanoic acids for use in influenza viral infections | |
| EP3746444A1 (en) | Cycloalkyl substituted pyrazolopyrimidines having activity against rsv | |
| HK1236532B (zh) | 用於在流感病毒感染中使用的吲哚 | |
| HK1236532A1 (en) | Indoles for use in influenza virus infection | |
| CA3005921A1 (en) | Substituted-(pyrrolo[2,3-b]pyridin-3-yl)-pyrimidin derivatives and use thereof as inhibitors of influenza virus replication | |
| OA19823A (en) | Inhibitors of influenza viruses replication. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |